AU9064991A - Use of angiotensin ii receptor antagonists in the treatment of diabetic retinopathy - Google Patents
Use of angiotensin ii receptor antagonists in the treatment of diabetic retinopathyInfo
- Publication number
- AU9064991A AU9064991A AU90649/91A AU9064991A AU9064991A AU 9064991 A AU9064991 A AU 9064991A AU 90649/91 A AU90649/91 A AU 90649/91A AU 9064991 A AU9064991 A AU 9064991A AU 9064991 A AU9064991 A AU 9064991A
- Authority
- AU
- Australia
- Prior art keywords
- angiotensin
- treatment
- receptor antagonists
- diabetic retinopathy
- retinopathy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB909027211A GB9027211D0 (en) | 1990-12-14 | 1990-12-14 | Medicaments |
GB9027211 | 1990-12-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
AU9064991A true AU9064991A (en) | 1992-07-08 |
Family
ID=10687045
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU90649/91A Abandoned AU9064991A (en) | 1990-12-14 | 1991-12-12 | Use of angiotensin ii receptor antagonists in the treatment of diabetic retinopathy |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0561901A1 (en) |
JP (1) | JPH06503335A (en) |
AU (1) | AU9064991A (en) |
GB (1) | GB9027211D0 (en) |
WO (1) | WO1992010183A1 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5185351A (en) * | 1989-06-14 | 1993-02-09 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists |
NZ251741A (en) * | 1992-04-13 | 1997-06-24 | Zeneca Ltd | Use of angiotensin ii antagonists for treating disease conditions associated with impaired neuronal conduction velocity |
GB9208116D0 (en) | 1992-04-13 | 1992-05-27 | Ici Plc | Therapeutic agents |
AU1423795A (en) * | 1994-02-08 | 1995-08-29 | Novartis Ag | Treatment of normotensive glaucoma with angiotensin ii antagonists |
US5658734A (en) * | 1995-10-17 | 1997-08-19 | International Business Machines Corporation | Process for synthesizing chemical compounds |
WO2000010605A2 (en) * | 1998-08-20 | 2000-03-02 | Senju Pharmaceutical Co., Ltd. | Preventives or remedies for eye circulatory failure |
WO2000066161A1 (en) | 1999-04-28 | 2000-11-09 | Takeda Chemical Industries, Ltd. | Preventives / remedies / progression inhibitors for simplex retinopathy or preproliferating retinopathy |
US6800439B1 (en) | 2000-01-06 | 2004-10-05 | Affymetrix, Inc. | Methods for improved array preparation |
US6806361B1 (en) | 2000-03-17 | 2004-10-19 | Affymetrix, Inc. | Methods of enhancing functional performance of nucleic acid arrays |
US6833450B1 (en) | 2000-03-17 | 2004-12-21 | Affymetrix, Inc. | Phosphite ester oxidation in nucleic acid array preparation |
US7005259B1 (en) | 2000-06-01 | 2006-02-28 | Affymetrix, Inc. | Methods for array preparation using substrate rotation |
US6380377B1 (en) * | 2000-07-14 | 2002-04-30 | Applied Gene Technologies, Inc. | Nucleic acid hairpin probes and uses thereof |
US6596490B2 (en) | 2000-07-14 | 2003-07-22 | Applied Gene Technologies, Inc. | Nucleic acid hairpin probes and uses thereof |
EP1752450A1 (en) * | 2005-08-01 | 2007-02-14 | Merck Sante | Imidazole derivatives as fructose-1,6-bisphosphatase inhibitors and pharmaceutical compositions containing them |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
EA020466B1 (en) | 2007-06-04 | 2014-11-28 | Синерджи Фармасьютикалз Инк. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
EP2810951B1 (en) | 2008-06-04 | 2017-03-15 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
ES2624828T3 (en) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and others |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
CA2905438A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
PT3004138T (en) | 2013-06-05 | 2024-06-18 | Bausch Health Ireland Ltd | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5015651A (en) | 1988-01-07 | 1991-05-14 | E. I. Du Pont De Nemours And Company | Treatment of hypertension with 1,2,4-angiotensin II antagonists |
DK0403159T3 (en) * | 1989-06-14 | 2000-08-14 | Smithkline Beecham Corp | imidazolyl |
CA2018443A1 (en) * | 1989-06-14 | 1990-12-14 | Joseph A. Finkelstein | Imidazolyl-alkenoic acids |
US5294631A (en) | 1990-04-13 | 1994-03-15 | Smithkline Beecham Corporation | Substituted benzimidazoles useful as angiotension II receptor antagonists |
-
1990
- 1990-12-14 GB GB909027211A patent/GB9027211D0/en active Pending
-
1991
- 1991-12-12 EP EP92900718A patent/EP0561901A1/en not_active Withdrawn
- 1991-12-12 WO PCT/GB1991/002221 patent/WO1992010183A1/en not_active Application Discontinuation
- 1991-12-12 AU AU90649/91A patent/AU9064991A/en not_active Abandoned
- 1991-12-12 JP JP4501728A patent/JPH06503335A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO1992010183A1 (en) | 1992-06-25 |
JPH06503335A (en) | 1994-04-14 |
EP0561901A1 (en) | 1993-09-29 |
GB9027211D0 (en) | 1991-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU9064991A (en) | Use of angiotensin ii receptor antagonists in the treatment of diabetic retinopathy | |
AU9058591A (en) | Use of angiotensin ii receptor antagonists in the treatment of diabetic nephropathy | |
AU8374491A (en) | Angiotensin II receptor antagonists | |
CY2007001I1 (en) | MEDICINAL PREPARATION FOR USE IN THE TREATMENT OF DIABETES | |
AU649605B2 (en) | Retinal, derivatives and their therapeutic use | |
AU4673393A (en) | Use of 3-phenoxypyridine in the treatment of psychomotor stimulant addiction | |
IL122464A0 (en) | N-heteroaryl-pyridinesulonamide derivatives and their use as endothelin antagonists | |
EP0230370A3 (en) | Use of specific n-methyl-d-aspartate receptor antagonists in the prevention and treatment of neurodegeneration | |
HUP9802272A3 (en) | Benzimidazole compounds and their use as modulators of the gaba-a receptor complex | |
AU9069191A (en) | Use of angiotensin ii receptor antagonists in the prevention of restinosis | |
AU9065291A (en) | Use of angiotensin ii receptor antagonists in the treatment of macular degeneration | |
AU9084191A (en) | Use of angiotensin ii receptor antagonists in the treatment of hemorragic stroke | |
EP0547178A4 (en) | Novel cholecystokinin antagonists, their preparation and therapeutic use | |
AU9052991A (en) | Use of angiotensin ii antagonist in the treatment of infarction | |
AU4163693A (en) | Angiotension II receptor antagonists for the treatment of disturbances in cardiac rhythm | |
AU4163793A (en) | Angiotensin II receptor antagonists for the treatment and prophylaxis of coronary heart disease | |
AU9064191A (en) | Use of angiotensin ii receptor antagonists in the treatment of atheroma | |
AU9081691A (en) | Use of angiotensin ii antagonists in the treatment of angina pectoris | |
AU9069291A (en) | Use of angiotensin ii receptor antagonists for the preparation of a medicament for improving cognitive function | |
AU9071291A (en) | Use of angiotensin ii antagonists in the treatment of left ventricular hypertrophy | |
ZA902245B (en) | Azolylethylcyclopropanes,the preparation thereof and the use thereof as crop protection agents | |
AU4585993A (en) | Use of angiotensin ii antagonists for the treatment of hyperlipidaeme | |
AU6281298A (en) | Use of lofexidine in the treatment of behavioral disorders | |
AU6901191A (en) | Pharmacologically active substance bpc, the process for its preparation and its use in the therapy | |
AU2641288A (en) | Methods and compositions for activating the human insulin receptor kinase |